1. Spyre Therapeutics will present at Jefferies Global Healthcare Conference. 2. Goldman Sachs conference will feature management on June 9, 2025. 3. Spyre focuses on innovative treatments for Inflammatory Bowel Disease (IBD). 4. Company's pipeline includes extended half-life antibodies targeting specific proteins.
Participation in conferences can enhance visibility and attract potential investors. Historical examples show that similar announcements often lead to positive price movements in biotech stocks.
The participation in high-profile conferences indicates strong company positioning and potential for investment interest.
The upcoming conferences are near-term events that can quickly influence investor sentiment.
(the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced that management will participate in the following upcoming investor conferences:
Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.
Spyre Therapeutics is a biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com.
Follow Spyre Therapeutics on social media: @spyretx and LinkedIn